Is intravenous (IV) deriphylline (theophylline) effective in treating tachycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Deriphylline (Theophylline) Should NOT Be Used to Treat Tachycardia—It Actually CAUSES Tachycardia

Intravenous deriphylline (theophylline/aminophylline) is contraindicated for treating tachycardia because theophylline itself is a well-established cause of tachyarrhythmias, particularly multifocal atrial tachycardia (MAT) and supraventricular tachycardia. 1, 2

Why Theophylline Causes—Rather Than Treats—Tachycardia

Theophylline as an Arrhythmogenic Agent

  • Theophylline therapy is explicitly listed as a common cause of multifocal atrial tachycardia in the 2015 ACC/AHA/HRS guidelines, alongside pulmonary disease, hypomagnesemia, and structural heart disease. 1

  • Discontinuation of theophylline resolves MAT in patients taking the drug—in a study of 16 patients with MAT on theophylline, the atrial rate fell and MAT resolved in all 16 patients after stopping the medication. 2

  • Rechallenge with aminophylline (IV theophylline) reproduces the arrhythmia—when 5 patients were given IV aminophylline after their MAT resolved, all 5 developed MAT with rapid ventricular response, even when serum levels were in the "therapeutic range" (10-20 mg/L). 2

  • Theophylline has a dose-dependent effect on atrial rate and ectopic activity, meaning higher doses worsen tachycardia. 2

Mechanism of Arrhythmogenesis

  • Theophylline antagonizes adenosine A1-receptors, which are critical for terminating supraventricular tachycardias—this is why adenosine (the first-line drug for SVT) may be ineffective in patients on theophylline. 3, 4

  • Theophylline toxicity can precipitate life-threatening SVT storms that are refractory to standard treatments including adenosine and electrical cardioversion, requiring mechanical circulatory support and hemodialysis to remove the drug. 4

Correct Management of Tachycardia

For Supraventricular Tachycardia (SVT)

  • Adenosine is the recommended first-line drug for acute treatment of hemodynamically stable SVT (150-200 mcg/kg rapid IV bolus), with a Class I recommendation. 1

  • IV beta-blockers, diltiazem, or verapamil are reasonable alternatives for acute SVT treatment in stable patients (Class IIa recommendation). 1

  • Immediate synchronized cardioversion is indicated for hemodynamically unstable patients. 1

For Multifocal Atrial Tachycardia (MAT)

  • First-line treatment is management of the underlying condition—if the patient is on theophylline, STOP IT. 1

  • IV metoprolol or verapamil can be useful for acute treatment of MAT (Class IIa recommendation), but only after addressing precipitating factors like theophylline. 1

  • IV magnesium may be helpful even in patients with normal magnesium levels. 1

For Ventricular Tachycardia (VT)

  • Immediate synchronized cardioversion for unstable VT with pulse. 5

  • IV amiodarone or lidocaine for stable VT—lidocaine 1-1.5 mg/kg bolus followed by infusion, or amiodarone 150 mg over 10 minutes. 6, 5

Critical Clinical Pitfall

If a patient presents with tachycardia and is taking theophylline/deriphylline, the drug is likely CAUSING the arrhythmia, not treating it. 1, 2 Check serum theophylline levels immediately and consider discontinuation. In severe theophylline toxicity with refractory tachyarrhythmias, propranolol and verapamil have been used successfully to control supraventricular tachycardia, and charcoal hemoperfusion or hemodialysis may be necessary. 4, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cardiac Arrhythmia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Ventricular Tachycardia Storm

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.